MAGELLAN LONGEVITY
HomeResearchStudy library › Elevated serum uric acid and risk of cardiovascular or all-cause…
Study summary · Cardiovascular & vascular aging

Does elevated serum uric acid (SUA) increase the risk of cardiovascular or all-cause mortality in maintenance hemodialysis patients?

Nutr Metab Cardiovasc Dis · 2020 · PMID 33485730 · DOI 10.1016/j.numecd.2020.11.017

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Higher serum uric acid levels are linked to a lower risk of cardiovascular death in hemodialysis patients.

The question

Does elevated serum uric acid (SUA) increase the risk of cardiovascular or all-cause mortality in maintenance hemodialysis patients?

What they tested

The meta-analysis aimed to determine if higher SUA values are a risk factor for cardiovascular or all-cause mortality in maintenance hemodialysis patients, given inconsistent results from previous studies.

How they did it

A meta-analysis was conducted by searching Pubmed, Embase, and the Cochrane library up to August 31, 2020, for longitudinal studies investigating the association between elevated SUA and cardiovascular or all-cause mortality risk in maintenance hemodialysis patients. Pooled adjusted hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a random-effects model. Ten studies with 264,571 hemodialysis patients were included.

What they found

Patients with the highest SUA levels had a decreased risk of cardiovascular mortality (HR = 0.72, 95% CI 0.59-0.87) compared to those with the lowest SUA, after adjusting for confounders. For every 1 mg/dl increase in SUA, the overall risks of all-cause and cardiovascular mortality decreased by 6% (HR = 0.94, 95% CI 0.90-0.99) and 9% (HR = 0.91, 95% CI 0.89-0.94), respectively.

Impact of 1 mg/dl Increase in Serum Uric Acid on Mortality Risk
Values shown: Percentage Decrease in Risk
All-cause mortality risk decrease6
Cardiovascular mortality risk decrease9

For each 1 mg/dl increase in serum uric acid, the risk of all-cause mortality decreased by 6% and cardiovascular mortality decreased by 9%.

What it means

Elevated SUA levels are strongly and independently associated with a lower risk of cardiovascular mortality in maintenance hemodialysis patients.

Limitations

The study suggests that more designed studies, especially randomized controlled trials, are needed to definitively determine if high SUA levels are an independent risk factor for all-cause mortality in hemodialysis patients.

“Elevated serum uric acid levels are strongly and independently associated with cardiovascular mortality risk”— from the published abstract, Nutr Metab Cardiovasc Dis 2020

The paper at a glance

TitleElevated serum uric acid and risk of cardiovascular or all-cause mortality: a meta-analysis
JournalNutr Metab Cardiovasc Dis
Year2020
PMID33485730 ↗
DOI10.1016/j.numecd.2020.11.017 ↗
TopicCardiovascular & vascular aging

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does elevated serum uric acid (SUA) increase the risk of cardiovascular or all-cause mortality in maintenance hemodialysis patients? [Plain-English summary of Nutr Metab Cardiovasc Dis 2020, PMID 33485730, DOI 10.1016/j.numecd.2020.11.017]. Magellan Longevity. https://magellanlongevity.com/study/d33485730.html
BibTeX
@misc{magellan_d33485730, title = {Does elevated serum uric acid (SUA) increase the risk of cardiovascular or all-cause mortality in maintenance hemodialysis patients?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d33485730.html}}, note = {Plain-English summary of PubMed PMID 33485730; DOI 10.1016/j.numecd.2020.11.017; Nutr Metab Cardiovasc Dis 2020. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d33485730.html

Related studies in the Magellan library

All 67 Magellan summaries on cardiovascular & vascular aging →

How this summary was made. Every section above restates what the published abstract of PMID 33485730 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.